Universal Vision Biotechnology Co Ltd (TWO:3218) — Market Cap & Net Worth
Market Cap & Net Worth: Universal Vision Biotechnology Co Ltd (3218)
Universal Vision Biotechnology Co Ltd (TWO:3218) has a market capitalization of $355.02 Million (NT$11.27 Billion) as of June 17, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #14157 globally and #596 in its home market, demonstrating a 1.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Universal Vision Biotechnology Co Ltd's stock price NT$133.00 by its total outstanding shares 84724899 (84.72 Million). Review 3218 liabilities breakdown to assess the company's total debt and financial obligations.
Universal Vision Biotechnology Co Ltd Market Cap History: 2015 to 2026
Universal Vision Biotechnology Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $44.54 Million to $355.02 Million (21.05% CAGR).
Universal Vision Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Universal Vision Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.09x
Universal Vision Biotechnology Co Ltd's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.37x
Universal Vision Biotechnology Co Ltd's market cap is 0.37 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $43.52 Million | $1.07 Billion | $91.80 Million | 0.04x | 0.47x |
| 2017 | $52.90 Million | $1.08 Billion | $120.09 Million | 0.05x | 0.44x |
| 2018 | $52.37 Million | $1.19 Billion | $161.48 Million | 0.04x | 0.32x |
| 2019 | $145.77 Million | $1.42 Billion | $238.00 Million | 0.10x | 0.61x |
| 2020 | $530.02 Million | $2.05 Billion | $483.21 Million | 0.26x | 1.10x |
| 2021 | $636.64 Million | $2.63 Billion | $595.43 Million | 0.24x | 1.07x |
| 2022 | $718.49 Million | $3.49 Billion | $850.53 Million | 0.21x | 0.84x |
| 2023 | $719.49 Million | $4.08 Billion | $1.05 Billion | 0.18x | 0.69x |
| 2024 | $533.86 Million | $4.23 Billion | $1.06 Billion | 0.13x | 0.50x |
| 2025 | $389.72 Million | $4.20 Billion | $1.04 Billion | 0.09x | 0.37x |
Competitor Companies of 3218 by Market Capitalization
Companies near Universal Vision Biotechnology Co Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to Universal Vision Biotechnology Co Ltd by market ranking:
- HCA Healthcare, Inc. (NYSE:HCA): Ranked #327 globally with a market cap of $80.16 Billion USD.
- FRESENIUS SE+CO. ADR 1/4 (F:FREA): Ranked #1003 globally with a market cap of $26.87 Billion USD ( €22.98 Billion EUR).
- Fresenius SE & Co. KGaA (XETRA:FRE): Ranked #1050 globally with a market cap of $25.53 Billion USD ( €21.84 Billion EUR).
- IHH Healthcare Bhd (KLSE:5225): Ranked #1333 globally with a market cap of $19.50 Billion USD ( RM77.67 Billion MYR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #327 | HCA Healthcare, Inc. | NYSE:HCA | $80.16 Billion | $396.93 |
| #1003 | FRESENIUS SE+CO. ADR 1/4 | F:FREA | $26.87 Billion | €10.20 |
| #1050 | Fresenius SE & Co. KGaA | XETRA:FRE | $25.53 Billion | €38.77 |
| #1333 | IHH Healthcare Bhd | KLSE:5225 | $19.50 Billion | RM8.79 |
Universal Vision Biotechnology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Universal Vision Biotechnology Co Ltd's market cap moved from $44.54 Million to $ 355.02 Million, with a yearly change of 21.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$355.02 Million | -8.90% |
| 2025 | NT$389.72 Million | -27.00% |
| 2024 | NT$533.86 Million | -25.80% |
| 2023 | NT$719.49 Million | +0.14% |
| 2022 | NT$718.49 Million | +12.86% |
| 2021 | NT$636.64 Million | +20.12% |
| 2020 | NT$530.02 Million | +263.61% |
| 2019 | NT$145.77 Million | +178.34% |
| 2018 | NT$52.37 Million | -1.01% |
| 2017 | NT$52.90 Million | +21.55% |
| 2016 | NT$43.52 Million | -2.28% |
| 2015 | NT$44.54 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Universal Vision Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $355.02 Million USD |
| MoneyControl | $355.02 Million USD |
| MarketWatch | $355.02 Million USD |
| marketcap.company | $355.02 Million USD |
| Reuters | $355.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical instruments, eyeglasses, contact lenses, and eyeglass accessories. It is also involved in eyeglasses optometry and dispensing services and leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy analysis, as we… Read more